Innate Pharma

Yahoo Finance • 12 months ago

15 Undervalued Defensive Stocks For 2024

In this article, we discuss the 15 undervalued defensive stocks for 2024. To skip the detailed overview of the market and defensive stocks, go directly to the 5 Undervalued Defensive Stocks For 2024. Defensive stocks are shares of compani... Full story

Yahoo Finance • last year

Innate Pharma S.A. (NASDAQ:IPHA) Q3 2023 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Thank you for standing by, and welcome to the Innate Pharma Third Quarter 2023 Financial Results and Business Update. I would now like to welcom... Full story

Yahoo Finance • last year

First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Partner Sanofi advances SAR’514 / IPH6401, a trifunctional anti-BCMA NKp46xCD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, to first-in-human clinical trial in relapsed/refractory Multiple Myeloma... Full story

Yahoo Finance • last year

Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023

MARSEILLE, France, July 07, 2023--(BUSINESS WIRE)--Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "A... Full story

Yahoo Finance • last year

Innate Pharma: First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer

Phase 2 MATISSE trial is evaluating IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with Imfinzi (durvalumab) and chemotherapy in early stage lung cancer IPH5201 is developed in collaboration with AstraZeneca MARSEILLE,... Full story

Yahoo Finance • last year

First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer

Phase 2 MATISSE trial is evaluating IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with Imfinzi (durvalumab) and chemotherapy in early stage lung cancer IPH5201 is developed in collaboration with AstraZeneca MARSEILLE,... Full story

Yahoo Finance • 2 years ago

Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria

Efficacy results presented at the 17th International Conference on Malignant Lymphoma, have been analysed according to updated lymph node involvement classification and confirm clinical activity and favorable safety profile of lacutamab in... Full story

Yahoo Finance • 2 years ago

Innate Pharma Reports First Quarter 2023 Financial Results and Business Update

Exclusive worldwide rights granted to Takeda to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies; Innate to receive $5m upfront payment and eligible to up to $410m in future milestonesplus roy... Full story

Yahoo Finance • 2 years ago

Innate Pharma to Participate in Upcoming Investor Conference

MARSEILLE, France, April 21, 2023--(BUSINESS WIRE)--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its senior management team are scheduled to participate in the following u... Full story

Yahoo Finance • 2 years ago

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2022 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2022 Earnings Call Transcript March 23, 2023 Operator: Ladies and gentlemen, thank you for standing by. My name is Brent and I will be your conference operator today. At this time, I would like to welco... Full story

Yahoo Finance • 2 years ago

Number of Shares and Voting Rights of Innate Pharma as of August 1, 2022

MARSEILLE, France, August 08, 2022--(BUSINESS WIRE)--Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or... Full story

Yahoo Finance • 3 years ago

Innate Pharma Reports First Quarter 2022 Financial Results and Business Update

First patient dosed in monalizumab Phase 3 lung cancer trial, PACIFIC-9 sponsored by AstraZeneca, which triggered a $50 million milestone payment extending Company cash runway into 2024 Monalizumab data presented by AstraZeneca at AACR and... Full story

Yahoo Finance • 3 years ago

Number of Shares and Voting Rights of Innate Pharma as of May 1, 2022

MARSEILLE, France, May 10, 2022--(BUSINESS WIRE)--Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AM... Full story